R. Levin

Publications10
h-index3
Citations183
Highly Influential Citations8
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Newacheck
  • 195 Publications • 17,688 Citations
  • Y. Verlinsky
  • 241 Publications • 7,074 Citations
  • J. Cramer
  • 258 Publications • 20,010 Citations
  • A. Karter
  • 264 Publications • 17,414 Citations
  • Publications
  • Influence
Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database
OBJECTIVE Adults with diabetes typically take multiple medications for hyperglycemia, diabetes-associated conditions, and other comorbidities. Medication adherence is associated with improved… Expand
  • 163
  • 6
  • PDF
Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence.
BACKGROUND Although the recommended treatment of hepatitis C continues to evolve as newer and more effective medications are made available, hepatitis C drug regimens consisting of a 3-drug… Expand
  • 8
  • 2
Improvements in Asthma Pharmacotherapy and Self-Management
Background and objectiveIn day-to-day practice, asthma treatment and self-management often fall short of the objectives defined by clinical practice guidelines. The objective of this study was to… Expand
  • 11
PDB93 THE RELIABILITY OF PROPORTION OF DAYS COVERED CALCULATIONS USING DEFINED DAILY DOSE ESTIMATES
PND31 IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS INTERFERON Â-1A FOR MULTIPLE SCLEROSIS PATIENTS USING A MAIL-ORDER PHARMACY
for Sweden [1]. Sensitivity analysis was associated with ICERs ranging up to SEK 900,000 (c93,856) per QALY gained. CONCLUSIONS: Due to the data limitations, HE modeling in the orphan drug setting is… Expand
PRO97 CLINICAL AND ECONOMIC BURDEN OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS) IN THE US: RESULTS FROM OPTUM CLAIMS
The use of Pharmacy claims data as an early indicator of Bioequivalence issues for newly launched Generic Medications
PCN102 Healthcare Resource Utilization (HCRU) and Costs with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIS) and Subsequent Chemotherapy Among Patients with LUNG Cancer
Quetiapine Off-Label Use
  • 1
PCV65 HOSPITALIZATIONS AND MORTALITY AMONG CARDIAC AMYLOIDOSIS PATIENTS COVERED BY MEDICARE ADVANTAGE